About
<p>Aramon Neuro-Medical develops a new drug formulation administered with a medical device that will be used in patients who are resistant to oral dopamine treatment. This is a problem that currently affects about 10% of Parkinson's patients and is considered to be one of the largest unmet medical needs in the field of Parkinson's disease.</p> <p>Aramon’s compound is a short-acting DA, which physicochemical properties and outstanding potency make it an excellent candidate for continuous subcutaneous (sc) infusion at low doses and volumes. It can be administered by a portable minipump or a patch-pump with daily doses of only about 1mg. This permits a ‘tailor-made’ individualized treatment. It also has strong 5-HT1A agonist effects with anti-dyskinetic properties.</p> <p>Significant and quite relevant improvement in ‘OFF’ time and in dyskinesias has been reported in prospective randomized trials (compared to high-dosed oral L-DOPA) and in this way a sc infusion of the compound avoids the risks of percutaneous enterogastrostomy (PEG), which is necessary for a continuous infusion of L-DOPA, and/or brain surgery (‘Deep Brain Stimulation’, DBS).</p>
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Aramon Neuro-Medical's primary focus in drug development?
- Aramon Neuro-Medical develops a new drug formulation, administered with a medical device, for Parkinson's patients resistant to oral dopamine treatment. This addresses a significant unmet medical need for approximately 10% of Parkinson's patients.
- What is the status of Aramon Neuro-Medical?
- Aramon Neuro-Medical is currently inactive, with its status changed to 'Non Active' in April 2014.
- Where is Aramon Neuro-Medical headquartered?
- Aramon Neuro-Medical is headquartered in Zikhron Ya'akov, Israel, at Rehov Ma'ale HaCarmel 2.
- What is the current development stage of Aramon Neuro-Medical's product?
- Aramon Neuro-Medical's product is in the R&D stage, and the company is currently in a 'Pre-Funding' stage.
- What type of compound does Aramon Neuro-Medical use in its drug formulation?
- Aramon Neuro-Medical's compound is a short-acting DA with physicochemical properties and potency suitable for continuous subcutaneous infusion at low doses and volumes.
- How is Aramon Neuro-Medical's drug formulation administered?
- Aramon Neuro-Medical's drug formulation can be administered by a portable minipump or a patch-pump, with daily doses of approximately 1mg, allowing for individualized treatment.
- What benefits does Aramon Neuro-Medical's subcutaneous infusion offer compared to existing treatments?
- Aramon Neuro-Medical's subcutaneous infusion avoids the risks associated with percutaneous enterogastrostomy (PEG) for continuous L-DOPA infusion and brain surgery (Deep Brain Stimulation, DBS).
- When was Aramon Neuro-Medical founded?
- Aramon Neuro-Medical was founded in January 2013.